MX2024004961A - Terapia de combinacion de complejo de radionuclidos. - Google Patents
Terapia de combinacion de complejo de radionuclidos.Info
- Publication number
- MX2024004961A MX2024004961A MX2024004961A MX2024004961A MX2024004961A MX 2024004961 A MX2024004961 A MX 2024004961A MX 2024004961 A MX2024004961 A MX 2024004961A MX 2024004961 A MX2024004961 A MX 2024004961A MX 2024004961 A MX2024004961 A MX 2024004961A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- combination therapy
- radionuclide complex
- efficient amount
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272447P | 2021-10-27 | 2021-10-27 | |
| PCT/IB2022/060331 WO2023073603A1 (en) | 2021-10-27 | 2022-10-27 | Combination therapy of radionuclide complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004961A true MX2024004961A (es) | 2024-05-08 |
Family
ID=84365353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004961A MX2024004961A (es) | 2021-10-27 | 2022-10-27 | Terapia de combinacion de complejo de radionuclidos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250387523A1 (enExample) |
| EP (1) | EP4422701A1 (enExample) |
| JP (1) | JP2024539952A (enExample) |
| KR (1) | KR20240093832A (enExample) |
| CN (1) | CN118159304A (enExample) |
| AU (1) | AU2022374887A1 (enExample) |
| CA (1) | CA3234495A1 (enExample) |
| IL (1) | IL312106A (enExample) |
| MX (1) | MX2024004961A (enExample) |
| TW (1) | TW202332473A (enExample) |
| WO (1) | WO2023073603A1 (enExample) |
-
2022
- 2022-10-27 CA CA3234495A patent/CA3234495A1/en active Pending
- 2022-10-27 KR KR1020247016801A patent/KR20240093832A/ko active Pending
- 2022-10-27 CN CN202280069041.9A patent/CN118159304A/zh active Pending
- 2022-10-27 EP EP22814157.8A patent/EP4422701A1/en active Pending
- 2022-10-27 WO PCT/IB2022/060331 patent/WO2023073603A1/en not_active Ceased
- 2022-10-27 IL IL312106A patent/IL312106A/en unknown
- 2022-10-27 AU AU2022374887A patent/AU2022374887A1/en active Pending
- 2022-10-27 US US18/704,804 patent/US20250387523A1/en active Pending
- 2022-10-27 TW TW111140975A patent/TW202332473A/zh unknown
- 2022-10-27 MX MX2024004961A patent/MX2024004961A/es unknown
- 2022-10-27 JP JP2024524610A patent/JP2024539952A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250387523A1 (en) | 2025-12-25 |
| CA3234495A1 (en) | 2023-05-04 |
| CN118159304A (zh) | 2024-06-07 |
| WO2023073603A1 (en) | 2023-05-04 |
| AU2022374887A1 (en) | 2024-04-11 |
| TW202332473A (zh) | 2023-08-16 |
| JP2024539952A (ja) | 2024-10-31 |
| IL312106A (en) | 2024-06-01 |
| EP4422701A1 (en) | 2024-09-04 |
| KR20240093832A (ko) | 2024-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4327882A3 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| MX2024013526A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t | |
| PH12021551833A1 (en) | Enpp1 inhibitors and methods of modulating immune response | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| ATE424221T1 (de) | Verfahren und vorrichtung für strahlentherapie | |
| WO2010121153A3 (en) | Biocompatible microbubbles to deliver radioactive compounds to tumors, atherosclerotic plaques, joints and other targeted sites | |
| MXPA05011656A (es) | Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma, o angiogenesis. | |
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| WO2022195489A3 (en) | Improved methods for the use of psychedelics | |
| WO2001074440A3 (en) | Methods and computer readable medium for improved radiotherapy dosimetry planning | |
| EA201290846A1 (ru) | Лучевая терапия, комбинированная с сенсибилизаторами гипоксической клетки | |
| EA201100626A1 (ru) | Лечение рака с помощью ионизирующего облучения и иммуноцитокинов | |
| CY1111565T1 (el) | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 | |
| MX2013007171A (es) | Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias. | |
| UA86586C2 (ru) | Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
| PL362795A1 (en) | Photochemical internalization for virus-mediated molecule delivery into the cyosol | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| PH12014500094A1 (en) | Combination als therapy | |
| MX2019007727A (es) | Reducción del daño de la radioterapia y aumento de las tasas de destrucción de cáncer entremezclando sesiones de baja y alta dosis. | |
| MX2025009185A (es) | Metodos para el tratamiento del glioblastoma | |
| MX2023001233A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. | |
| MX2022014886A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. | |
| MX2024006078A (es) | Metodo para tratar el cancer con acilfulveno y radiacion. |